"chemotherapy response scores" trang 1 - tải miễn phí từ tailieunhanh
Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy

Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy
8    64    1
Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
9    102    0
Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: A randomized controlled trial

Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: A randomized controlled trial
13    41    1
Hormetic and synergistic effects of cancer treatments revealed by modelling combinations of radio - or chemotherapy with immunotherapy

Hormetic and synergistic effects of cancer treatments revealed by modelling combinations of radio - or chemotherapy with immunotherapy
14    6    1
Predicting the response to neoadjuvant chemotherapy for breast cancer: Wavelet transforming radiomics in MRI

Predicting the response to neoadjuvant chemotherapy for breast cancer: Wavelet transforming radiomics in MRI
10    74    0
Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer

Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer
7    63    0
RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial

RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial
7    75    0
Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: A large, multicenter, observational study

Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: A large, multicenter, observational study
11    49    1
A nomogram based on platelet-tolymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy

A nomogram based on platelet-tolymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy
9    2    1
Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer

Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer
11    10    1
Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: A systematic review

Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: A systematic review
21    1    1
Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy

Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy
19    10    1
CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy
11    66    0
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients

The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients
11    37    1
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
9    1    1
Tumor-infiltrating CD36+CD8+T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer

Tumor-infiltrating CD36+CD8+T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer
13    3    1
A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients

A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients
13    11    1
Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk (“ugly”) locally advanced rectal cancer: Study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)

Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk (“ugly”) locally advanced rectal cancer: Study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)
11    28    1
Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: A retrospective study

Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: A retrospective study
11    60    0
Valuation of the CT LI-RADS treatment response V2018 in patients after first-line deb tace) for hepatocellular carcinoma (HCC)

Valuation of the CT LI-RADS treatment response V2018 in patients after first-line deb tace) for hepatocellular carcinoma (HCC)
8    1    1